Novo Nordisk strikes second licensing deal since frosty capital-markets day
Why now
Thesis: Novo buys pipeline to counter investor doubts
Catalyst to watch: Deal terms and pipeline data
Main risk: Deals fail to offset core franchise worries
Why it matters
Repeated licensing deals after a poor capital-markets day signal Novo is buying pipeline to offset investor skepticism.
Details
Novo Nordisk on Tuesday struck its second licensing deal since receiving a poor reception from investors after presenting its long-term strategy.
Sources
- marketwatch · 2026-09-29 09:45 UTC